

FDA: opioid antidote naloxone recalled

June 6 2018



(HealthDay)—A recall of the opioid overdose antidote Naloxone was announced Monday. The U.S. Food and Drug Administration said the recall was triggered by the possibility of "loose particulate matter on the

syringe plunger" that could pose a number of health risks, *CNN* reported.

Those risks include "local irritation, allergic reactions," and a range of cardiovascular issues, including blood clots, according to the FDA. The agency has not received any reports of patient harm from the recalled Naloxone, made by Hospira.

The recall covers single use sterile cartridge units with lot numbers 72680LL and 76510LL in 0.4 mg/mL and 1 mL in 2.5 mL strengths that were distributed to wholesalers, distributors, and hospitals in the United States, Puerto Rico, and Guam between February 2017 and February 2018, *CNN* reported.

Hospira said distributors and retailers should not use or distribute the recalled Naloxone and should alert stores, pharmacies, and hospitals and others who have received it.

More information: [More Information](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: FDA: opioid antidote naloxone recalled (2018, June 6) retrieved 6 May 2024 from <https://medicalxpress.com/news/2018-06-fda-opioid-antidote-naloxone-recalled.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
